Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

Esophageal Catheters Market. The global esophageal catheters market is poised for significant expansion, with a projected market value of USD 2.2 billion in 2022, and a robust com ...

Sanofi “Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing standard of care treatment options, and, as a result, many of these young patients ...

We are pleased that research continues and offers new treatment options to improve the quality of their care.” “Eosinophilic esophagitis presents a unique challenge in young children ...

which was sustained up to one year Dupixent is the first-ever medicine in the EU indicated to treat these young patients, who persistently struggle to eat at a critical stage in life where growth ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years ...

We are pleased that research continues and offers new treatment options to improve the quality of their care.” "Up to half of all children in the EU with eosinophilic esophagitis remain uncontrolled ...